Ongoing review of cholesterol drug Vytorin

The U.S. Food and Drug Administration (FDA) is informing the public that the agency will conduct a review of Merck and Schering Plough's recent trial once the FDA receives the final study results.

The U.S. Food and Drug Administration issued an Early Communication regarding the agency's ongoing review of Vytorin based on preliminary results from a recently completed study – the Effect of Combination Ezetimibe and High-Dose Simvastatin vs. Simvastatin Alone on the Atherosclerotic Process in Patients with Heterozygous Familial Hypercholesterolemia (ENHANCE) – on this cholesterol lowering drug. Vytorin contains both Zetia (ezetimibe) and Zocor (simvastatin) in one tablet.

Merck/Schering Plough Pharmaceuticals issued a press release reporting preliminary results of the study and stated that the study demonstrated no significant differences between the combination product and Zocor on the build up of cholesterol plaque in the carotid (neck) arteries. The study was not designed to detect any difference in risk of having a heart attack or stroke between the two treatments. An ongoing trial called -- Improved Reduction of Outcomes: Vytorin Efficacy International Trial (IMPROVE IT) -- is underway which is designed to evaluate the effect of Vytorin versus Zocor on heart disease and stroke.

This Early Communication is in keeping with the FDA's commitment to inform the public about its ongoing review of drugs. Until the FDA reviews the data, the agency advises patients to talk with their health care providers if they have questions about the ENHANCE study.

Full text of the Early Communication about an Ongoing Data Review for the ENHANCE Study can be found at: http://www.fda.gov/cder/drug/early_comm/ezetimibe_simvastatin.htm.

(Published at Health News Track on January 25, 2008 - 346 days ago)

Cholesterol article/news source:

U.S. Food and Drug Administration - read other health news articles from U.S. Food and Drug Administration and health news articles from USA.

Cholesterol - related articles/news stories:

- 12 new genes identified for managing cholesterol, glucose, melatonin, sleep
- Lower cholesterol early in life
- Cholesterol and blood pressure control may reverse atherosclerosis
- Lowering cholesterol reduces heart attack and stroke risk
- Cholesterol drug statins may reduce heart's atrial fibrillation
- Cholesterol lowering drug may fight staph infection
- Vytorin does not appear to be unsafe - American Heart Association
- Statins, cholesterol lowering drugs may not prevent Alzheimer's Disease
- Combined with exercise, cholesterol increase muscles


»» Manuka honey with natural antibacterial methylglyoxal
«« Middle class women earning more, drinking more

The information provided on Health Newstrack is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.
We comply with the HONcode principles for trustworthy health information, verify here.
www.healthnewstrack.com - About us, Editorial team, Advertising, Jobs, Links, Privacy policy, Disclaimer, Feedback,
Site map, List health news, Health news organizations, Health news world, Accessibility, Glossary, Testimonials, Blog
Mobile/PDA Submit press release
© 2007-2008 HealthNewstrack.com
Track Health News Daily
1.76